MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Mac... (nistration may provide the patient withe...)

MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema

Date:10/1/2007

nistration may provide the patient with exposure to sirolimus for up to approximately three months.

In addition to safety and tolerability data, the study provided an initial assessment of sirolimus' biological activity in DME. At 45 and 90 days following treatment, patients receiving the two lowest doses of sirolimus by subconjunctival injection demonstrated mean improvements in visual acuity of 8.5 and 7.4 letters over baseline, respectively, using a standard (ETDRS) eye chart. Additionally, this group of patients also experienced anatomical improvements, with a mean decrease in foveal thickness that was consistent with the observed functional improvements in visual acuity. Preliminary data for these patients at 180 days following treatment suggest that these initial improvements in visual acuity and foveal thickness reductions were maintained, or even enhanced, over time in many patients.

"The fact that we are seeing measures of biological activity maintained, and, in some cases improving, through 180 days following a single subconjunctival injection, is somewhat surprising. This finding raises the possibility that sirolimus may be fundamentally changing the course of diabetic retinopathy through its impact on the mTOR (mammalian target of rapamycin) pathway rather than simply reversing macular edema in a more non-specific way," said Dr. Blumenkranz. "Further studies to support or refute this hypothesis will be necessary. However, if so, then the potential clinical utilization of the drug may eventually extend beyond those patients with clinically significant diabetic macular edema."

"The study's findings are intriguing, particularly in light of the fact that a majority of the participants had been previously treated for DME. As such, these results provide great excitement for researchers as we prepare to advance this product into Phase 2 clinical studies," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "We are
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:12/15/2009)... Calif., Dec. 15 Dakim, Inc. and Alzheimer,s ... for Loved Ones, Brain Health Contest, designed to help ... of dementia and Alzheimer,s disease. All five winners will ... designed specifically to help seniors preserve their brain health ... in senior living communities across the country. ...

(Date:12/15/2009)... NASHVILLE, Tenn., Dec. 15 Cumberland ... announced new top-line results for a ... for Oral Solution, a prescription laxative packaged as ... liquid forms. ,, Kristalose is the only prescription-strength ... 14-day period, 50 patients with a recent diagnosis ...

(Date:12/15/2009)... Dynatronics Corporation (Nasdaq: DYNT ) ... to provide therapy equipment and rehab supplies to ... of physical, occupational and speech therapy clinics. ,, ... Providers," said Larry K. Beardall, executive vice president ... network of 1,100 clinics is the largest rehabilitation ...

Breaking Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 2 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2 Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3 Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc. 2 Approved lymphoma drug shows promise in early tests against bone cancer 60780 1 Approved lymphoma drug shows promise in early tests against bone cancer 60780 2 Mom was right 3A Nice guys dont always finish last 60778 1 Mom was right 3A Nice guys dont always finish last 60778 2 Fetus Learns Intonations of Mothers Tongue 60775 1 Fetus Learns Intonations of Mothers Tongue 60775 2 Fetus Learns Intonations of Mothers Tongue 60775 3

[0] 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's [0] Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study [0] Dynatronics Inks Preferred Vendor Agreement with 1,100 Member Preferred Therapy Providers, Inc.

... First-in-class treatment for inhalation anthrax -ROCKVILLE, Md., May ... HGSI ) today announced that it has ... U.S. Food and Drug Administration (FDA) for its ... treatment of inhalation anthrax. (Logo: ...

... /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic ... first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will ... Biomarker Blood Test to Aid in Diagnosis, Treatment and ... Psychiatric Association Annual Meeting, May 20, 2009. The blood ...

Other Medicine Technology:Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 2 Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 3 Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM) 4 Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting 2

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting

(Date:12/15/2009)... still too early to say that phthalates ... Dec. 15 (HealthDay News) -- Common chemicals found ... the abnormal growth of breasts in boys, preliminary ... a prominent medical journal for pediatricians, adds fuel ... whose safety has been questioned by some scientists. ...

(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...

(Date:12/15/2009)... Accelify is proud to announce the addition ... David will serve as Director of Development in the ... Board of Advisors. ,, David Tokofsky was ... of Education in June 1995. As the Board Member ... 600,000 stretching from Northeast Los Angeles through East Los ...

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. As competitors ... complete a product portfolio they also must face ... ,, A new free, white paper from Howard ... Conservation Program: US Airways ," details how the ... the newly formed company to enhance its occupational ...

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... of Autoimmune Diseases Therapeutics - Market ... Pipeline and Deals Analysis ... Summary ,, The author has ...

[0] Breast Growth in Boys Might Be Linked to Plastics Chemical [0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... -- China Sky One,Medical, Inc. ("China Sky One ... a,leading fully integrated pharmaceutical company producing external use,over- ... ("PRC"),announced today that it signed an agreement with ... the Company,s prescription,drugs., China Sky One, which ...

... in trials, lengthens survival, study finds , , TUESDAY, July ... that fights malignant brain tumors called glioblastoma multiforme (GBM) ... the outcome, a new report says. , An ... Research says this would mark the first time ...

... Examines Controversial and Relevant Issues ... ... Retirement Living TV (RLTV), the,first network dedicated to people 55+, ... programming -- senior centric,investigative journalism. Viewpoint with Lea Thompson is ...

... a low-sodium diet does not appear to have any ... to new research. , "Despite the clear benefit of ... no therapeutic benefit in the use of a low-sodium ... E. K. Pogson, M.R.C.P., clinical research fellow at the ...

... Most relationships have some degree of,conflict or distance. The ... romantic relationships that end in heartbreak are countless., ... Ferguson states that when a,relationship isn,t working, there will ... that is creating the problem., Bill Ferguson says, ...

... CEO's, are all eagerly awaiting the opening of a new San ... ... 2008 -- Dr. Eben Davis, one of the most successful chiropractors ... bring his vision into reality. Peacock Construction has been in the ...

Other Medicine News:Health News:China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company 2 Health News:China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company 3 Health News:Brain Cancer Vaccine's Immune Response Key to Outcomes 2 Health News:Retirement Living TV Announces Series Premiere of Viewpoint with Lea Thompson on July 18, 2008 2 Health News:Low-sodium advice for asthmatics should be taken with a grain of salt 2 Health News:Bill Ferguson's New Book, Get Your Power Back: It Only Takes One Person to Heal a Difficult Relationship 2 Health News:Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center 2

China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company Brain Cancer Vaccine's Immune Response Key to Outcomes Retirement Living TV Announces Series Premiere of Viewpoint with Lea Thompson on July 18, 2008 Low-sodium advice for asthmatics should be taken with a grain of salt Bill Ferguson's New Book, Get Your Power Back: It Only Takes One Person to Heal a Difficult Relationship Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....

... Certified by an independent ... 100 specifications of Federal ... guarantees worker confort, reduces ... Clean vinyl meets Class ...

... Seat height: Bench high, 26-31". ... productivity. "Soft Touch" pnuematic control for ... with Static-control casters allow easy mobility. ... ; Decay (from 5000 Volts to ...

Medicine Products:

4V58-R 4V57-R Class 100 Chair Laboratory Chair

MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Mac...(nistration may provide the patient withe...),Health